A Phase 1/2 interventional study of IGT-303 and Placebo in Healthy Volunteers and Chronic Kidney Disease, sponsored by Ingenia Therapeutics INC. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Ingenia Therapeutics INC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Renal Insufficiency, Chronic with a site in Australia — 19 open to participants now, 29 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Australia.
Among the 102 studies in Renal Insufficiency, Chronic with a site in Australia, this one is the 73rd largest by planned enrollment of the 92 interventional ones that give a count, is one of 11 that started in 2025, is one of 3 in phase 1/2, reaches primary completion later than 8 of the 28 other live ones, and was the 96th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →19 of the 102 studies in Renal Insufficiency, Chronic with a site in Australia are open now. Recruiting first, the newest first:
Atom Therapeutics Co., Ltd · Sites in Australia, China
Ages 18–75
AstraZeneca · Sites in Australia, United States, Argentina and 34 more countries
Ages 18+
Cajal Therapeutics Inc. · Sites in Australia
Ages 18–55 · Healthy volunteers
Pulmongene Ltd. · Sites in Australia
Ages 18–55 · Healthy volunteers
Eli Lilly and Company · Sites in Australia, Argentina, Austria and 35 more countries
Ages 50+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 50 · Phase 4 4
First in 2003; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 347 across the 92 interventional studies, 1,175 across the 10 observational. Of the 69 that completed or were terminated, 41 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 102 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ingenia Therapeutics INC as lead sponsor.
Ingenia Therapeutics INC has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
11 of the studies in Renal Insufficiency, Chronic with a site in Australia that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 11 to your calendar (.ics) → With an account.
Among the 102 studies in Renal Insufficiency, Chronic with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is:
Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)).
Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use.
Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: single ascending dose (SAD), 6 cohorts Part B: multiple ascending dose (MAD), 3 cohorts
Drug: IGT-303
Placebo (normal saline)
Drug: Placebo
IGT-303 administered via IV or SC
Saline
Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs)
The number and severity (by Grade) will be measured.
Time frame: From Screening to Day 84.
PK Parameters of Intravenous (IV) and Subcutaneous (SC) IGT-303
Maximum observed concentration (Cmax)
Time frame: Day 1 to Day 84.
PK Parameters of IV and SC IGT-303
Observed time of maximum concentration (Tmax)
Time frame: Day 1 to Day 84
PK Parameters of IV and SC IGT-303
Terminal exponential rate constant, determined using the linear least squares regression of the terminal phase of the log-serum concentration time profile (λz)
Time frame: Day 1 to Day 84
PK Parameters of IV and SC IGT-303
Terminal exponential half-life, calculated as ln(2)/λz (T1/2)
Time frame: Day 1 to Day 84
PK parameters of IV and SC IGT-303
Area under the concentration-time curve calculated using linear trapezoidal rule from time zero to time t, where t is the time of the last observed quantifiable concentration (AUC0-t)
Time frame: Day 1 to Day 84
PK parameters of IV and SC IGT-303
Area under the concentration-time curve from time zero to infinity, defined as AUC0-t + Ct/λz (AUC0-∞)
Time frame: Day 1 to Day 84
PK parameters of IV and SC IGT-303
Total clearance (CL), defined as dose/AUC0-∞
Time frame: Day 1 to Day 84
PK parameters of IV and SC IGT-303
Terminal volume of distribution (Vz), defined as CL/λz
Time frame: Day 1 to Day 84
PK parameters of IV and SC IGT-303
Absolute bioavailability (F), defined as the dose-corrected (AUC0-∞ SC) / (AUC0-∞ IV)
Time frame: Day 1 to Day 84
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.
Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Oct 2026 → Dec 2026 and completion Jan 2027 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →